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Abstract 
In this work, we report the synthesis of novel cationic phosphonium gold nanoparticles 
dispersible in water and dimethylsulfoxide (DMSO) for their potential use in biomedical 
applications. All the cationic-functionalising ligands currently reported in the literature are 
ammonium-based species. Here, the synthesis and characterisation of an alternative system, 
based on phosphonioalkylthiosulfate zwitterions and phosphonioalkylthioacetate were carried 
out. We have also demonstrated that our phosphonioalkylthiosulfate zwitterions readily 
disproportionate into phosphonioalkylthiolates in situ during the synthesis of gold 
nanoparticles produced by the borohydride reduction of gold (III) salts. The synthesis of the 
cationic gold nanoparticles using these phosphonium ligands were carried out in water and 
DMSO. UV-Visible spectroscopic and TEM studies have shown that the 
phosphonioalkylthiolates bind to the surface of gold nanoparticles which are typically around 
10nm in diameter. The resulting cationic-functionalised gold nanoparticles are dispersible in 
aqueous medium and in DMSO, which is the only organic solvent approved by the U.S. Food 
and Drug Administration (FDA) for drug carrier tests. This indicates their potential future use 
in biological applications. This work shows the synthesis of a new family of phosphonium-
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based ligands, which behave as cationic masked thiolate ligands in the functionalisation of 
gold nanoparticles. These highly stable colloidal cationic phosphonium gold nanoparticles 
dispersed in water and DMSO can offer a great opportunity for the design of novel 
biorecognition and drug delivery systems. 
1. Introduction 
The ability of modifying noble metal nanoparticles, such as gold nanoparticles with various 
organic thiolate ligands makes them versatile systems and opens a range of possibilities for 
their use as drug delivery systems,
1-3
 and biosensing
4-6
 applications. Even though the use of 
these nanoparticles in therapeutic purposes is promising, challenges still remain and when 
designing drug nanocarriers, the following considerations are usually taking into account: (i) 
possible drawbacks due to free drugs, (ii) tissue permeation and cellular uptake, and (iii) 
homogenous distribution within the target tissues and organs.
7-13
 Therefore, for any 
biomedical application the main requirements are the affinity to aqueous media and 
compatibility with the immediate biological environment or appropriate receptor groups for 
sensing or diagnostic applications.  
Ligands are introduced to the surface of the nanoparticle either to stabilise the particle and 
avoid uncontrolled aggregation, or to add functionality to the particle for biomolecular 
recognition, enhance transport and anchoring properties.
7
 Recent studies have shown that the 
size, shape and surface charge of nanoparticles, in general, play crucial roles in their entry 
and subsequent access of nanoparticles into living cells.
6,13-16
 For instance, cationic 
nanoparticles are more effective penetrating into mammalian cells than anionic 
nanoparticles.
17
 Nanoparticle surface functionalisation plays an important role in the cellular 
uptake and producing cellular responses.
18,19
 However, information published in the literature 
on how functionalised nanoparticle surface characteristics, such as aromaticity and 
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hydrophobicity, affect cellular internalisation processes is still unclear. Al-Hajaj et al. have 
shown that the functionalised quantum dots they produced with non-specified ligands were 
taken up by lipid host mediated endocytosis in human kidney and liver cells.
20
 Designing and 
tailoring the surface of inorganic nanoparticles with suitable ligands may potentially offer 
long-term stability under a wide-range of conditions such as, high electrolyte concentration, a 
broad pH range, and biogenic or naturally occurring thiols.
3
 Zhan et al. have shown that 
quantum dots modified with multidentate lipoic ligand containing a zwitterionic head group 
can be highly biocompatible nanomaterials,
21-22
 making them attractive nanodevices for 
clinical in vitro and in vivo imaging applications.
23-25
  More recently, Rotello et al. have 
studied the behaviour of gold nanoparticles with different hydrophobicities and the effect of 
surface functionality on hemolysis.
26
 They observed a linear haemolytic behaviour with 
increasing hydrophobicity in the absence of serum media. McIntosh et al. synthesised gold 
nanoparticles capped with a mixture of octanethiol and 11-trimethylammonium-
undecanethiol, and others functionalised with trimethylammonium cationic head groups on 
the surface can interact electrostatically and bind with the negatively charged phosphate 
backbone of 37mer duplex DNA.
27
 As in these studies reported in the literature, the majority 
of the cationic species investigates and used are ammonium -based groups. Here in this work, 
we are proposing the use of cationic phosphonium-based groups as alternatives to the 
ammonium ones.  The phosphonium groups can offer a range of advantages including the 
availability of a broad range of organic derivatives, which allows of designing and producing 
a wide variety of functionalised gold nanoparticles. Their ability of triphenylphosphonium 
head groups to travel across cell membranes is well-known.
28-30
 There are also several studies 
on the use of phosphines and phosphine oxides to stabilise nanoparticles. However, there 
have been far fewer studies of the use of organophosphorus ligands.
31-33
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Additional to imparting specific functionalities to nanoparticles, their dispersion in water or 
any other biocompatible solvent is crucial for their use in biomedical or biological 
applications. Therefore, water should be the primary solvent to be used to disperse 
functionalised nanoparticles. However, in many cases, the ligands used to protect and provide 
functionality to nanoparticles, and the corresponding nanomaterials produced are not soluble 
or dispersible in water. It would be highly beneficial to have a range of other biocompatible 
solvents. One potential alternative to water may be dimethyl sulfoxide (DMSO). According 
to the FDA, DMSO is a solvent derived from wood, which has been the subject of 
considerable interest for its potential as a drug. At present, the only human use for which 
DMSO has been approved is for interstitial cystitis, a bladder condition. DMSO is also 
known as a "carrier" chemical, it could deliver substances into the bloodstream through the 
skin.
34
 For all the reasons outlined here, DMSO was a chosen solvent to synthesise and 
disperse our nanoparticles. 
Here in this paper we are reporting for the first time the syntheses cationic gold nanoparticles 
by reducing gold (III) salt in the presence of our cationic phosphonium ligands in DMSO. We 
also describe the synthesis of a new cationic phosphonium ligand, tri(p-
tolyl)phosphoniopropylthiosulfate zwitterion used to functionalise the gold nanoparticle 
surface in DMSO. Two previously reported phosphonium ligands, 
triphenylphosphoniopropylthiosulfate zwitterion
35
 and (3-
thioacetylpropyl)triphenylphosphonium bromide,
36
 were used for this work to produce the 
cationic phosphonium gold nanoparticles in DMSO and comparison purposes with the new 
ligand synthesised, tri(p-tolyl)phosphoniopropylthiosulfate.  
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2. Materials and Methods 
(a) General 
All chemicals and solvents were purchased from Sigma-Aldrich and Fisher Scientific Ltd. 
For the characterisation of the ligands and functionalised gold nanoparticles several analytical 
techniques were used. TLC, ATR-FTIR, NMR, ESI-MS techniques were employed to 
characterise the phosphonium containing ligands. UV-Visible spectroscopy and TEM were 
used to characterise and obtain the size of the cationic phosphonium gold nanoparticles. The 
stability of the colloidal gold nanoparticle solutions were monitored using UV-Visible 
technique. 
Thin Layer Chromatography (TLC): Analytical thin layer chromatography was carried out 
on Merck silica gel 60 F254 plates by using mixtures of methanol: dichloromethane (DCM) 
as eluent system. 
Attenuated Total Reflectance – Fourier Transform Infrared (ATR-FTIR) Spectroscopy: 
IR spectra acquisition was performed on solid samples using a Nicolet 5700 FT-IR 
spectrometer equipped with Omnic software (version 7.1) and a Smart Omni-Sampler (ATR 
cell with single reflectance germanium crystal). Each recorded spectrum is the average of 32 
scans with a spectral resolution of 4 cm
−1
 from 400 to 4000 cm
−1
 on a dried sample, with a 
background spectrum recorded before each analysis. Spectra were measured and analysed 
and fitted using Origin software (Version 7.5) equipped with Peak-Fitting Module (PFM). 
Nuclear Magnetic Resonance Spectroscopy (NMR): 
1
H NMR spectra were acquired on a 
JEOL 400MHz spectrometer. Data are reported as follows: s, singlet; d, doublet; t, triplet; q, 
quartet; m, multiplet. Appropriate solvents such as dimethylsulfoxide, chloroform, diethyl 
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ether were used to dissolve the samples to a concentration of 15 to 40 mg ml
-1
 for 
1
H 
experiments.  
Electrospray Ionisation – Mass Spectrometry (ESI-MS): ESI-MS analyses were generally 
performed on the Orbitrap XL using nano- electrospray in positive or negative ionisation 
mode. Orbitrap XL High resolution instrument gives accurate mass measurement over the 
full mass range in electrospray resolution: up to 100,000 (FWHM). Mass Range: m/z 50–
2000 or m/z 200–4000. Mass Accuracy: <3 ppm RMS with external calibration; <2 ppm 
RMS with internal calibration. 
All samples were initially solvated in 250µl of DCM before approximately 10µl of the 
solutions were added to 1ml of methanol with NH4OAc. A portion of these samples were 
added to a 96 well plate to be analysed by positive nano-electrospray.  
Ultraviolet-Visible Absorption Spectroscopy (UV-visible):  UV-visible spectra were 
obtained on a HITACHI U-2900 spectrophotometer with double beam principle system with 
data recording using Vision software version on Windows XP/2000. Samples were analysed 
in a UV-quartz cuvette of a 1 cm optical path. Appropriate dilutions to the original samples 
were carried out using either water or DMSO. 
Transmission Electron Microscopy (TEM): A JEOL2100 field emission gun transmission 
electron microscope (FEG TEM) set at 100 KV was used for the analyses of the particles and 
obtained the TEM micrographs. Size distribution was obtained by counting and measuring 
over 150 gold nanoparticles. Deposition method was used to prepare the samples for TEM 
analyses. A drop of a diluted colloidal solution of the functionalised gold nanoparticles was 
placed and suspended on a Holey carbon coated copper grid. Then the grids were left to dry 
at room temperature.  
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(b) Synthesis of Cationic Phosphonium Ligands 
The tri(p-tolyl)phosphoniopropylthiosulfate zwitterion synthesis and characterisation are 
reported for the first time in this work. The syntheses of the 
triphenylphosphoniopropylthiosulfate zwitterion and ω-thioacetylpropylphosphonium salt 
were carried out following previously reported methods.
35,36 
The synthetic protocols used to 
produce the three ligands are outlined in this section.  
Synthesis of tri(p-tolyl)phosphoniopropylthiosulfate  zwitterion 
The synthesis of the tri(p-tolyl)phosphoniopropylthiosulfate zwitterion was carried out 
following the reactions showed in Scheme 1. In a round bottom flask with a reflux condenser 
a mixture of tri(p-tolyl)phosphine (1) (3.8mmol) with approximately bromo-propanol (15 
mmol) were refluxed for five hours in acetonitrile (0.024 mmol) and the solid precipitate was 
collected and recrystallized from ethanol (Reaction 1, Scheme1). The yield was 70%. The 
resulting salt (2) was dissolved in hydrobromic acid (0.18 mmol, 10 ml) (48%) in a round 
bottom under reflux five hours (Reaction 2, Scheme 1). The reaction mixture was left to cool 
down, the compound appeared as yellow oil (3). In order to prepare the tri-p-
tolylphosphoniopropylthiosulfate zwitterion (4), a mixture of -bromopropyl-tri(p-
tolyl)phosphonium bromide (3) (1 mmol) and sodium thiosulfate (1.5 mmol) were refluxed 
for five hours in aqueous ethanol (1:1, 10ml) (Reaction 3, Scheme 1). TLC was used in order 
to follow the progress of the reaction by using 20%:80% methanol:DCM as mobile phase. All 
compounds were purified further by liquid-liquid extraction of the reaction mixture using 
DCM and by trituration with dry diethyl ether.  
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Scheme 1: Synthesis of tri(p-tolyl)phosphoniopropylthiosulfate zwitterion (4) 
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Synthesis of triphenylphosphoniopropylthiosulfate  
In order to obtain the triphenylphosphoniopropylthiosulfate zwiterion,
35
 three main chemical 
reactions were carried out. The first stage involved the synthesis of the 
hydorxylpropylphosphonium salt and this was generated by a quaternation reaction of 
triphenylphosphine (4 mmol) and the corresponding bromo-propanol (15 mmol) in 
acetonitrile under reflux for four to five hours. The resulting salt was dissolved in 
hydrobromic acid (48%) and reaction was carried out under reflux for five hours to obtain the 
ω-bromopropyltriphenylphosphonium bromide salt. The latter (1 mmol) then was treated 
with sodium thiosulfate (1.5 mmol) in ethanol/water under reflux for five hours in order to 
produce the phosphoniopropylthiosulfate zwitterion. Progress of all reactions were monitored 
by TLC using methanol:dichloromethane 1:4 ratio as the mobile phase. All the compounds 
were purified by dichloromethane extraction and re-crystallisation using diethyl ether.  
(CH2)3 S SO3P
Triphenylphosphoniopropylthiosulfate zwitterion 
Synthesis of (3-thioacetylpropyl)triphenylphosphonium bromide 
In order to obtain the (3-thioacetylpropyl)triphenylphosphonium bromide, 
hydroxypropylphosphonium and ω-bromopropyltriphenylphosphonium bromide salts were 
also synthesised as described in the synthesis of triphenylphosphoniopropylthiosulfate 
zwitterion.
35,36
 Once the bromide salt (2mmol) was produced, this was reacted with potassium 
thioacetate (3 mmol) in a mixture of ethanol/water. The progress of the reaction was followed 
by TLC using a mobile phase of methanol:dichloromethane  in 1:4 ratio. The (3-
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thioacetylpropyl)triphenylphosphonium bromide was isolated and purified by liquid-liquid 
extraction using DCM as the extracting solvent, and re-crystallisation of the bromide salt 
using diethyl ether. 
Br
(CH2)3 S C
O
CH3P
 (3-Thioacetylpropyl)triphenylphosphonium bromide 
 (c) Synthesis of cationic phosphonium gold nanoparticles in DMSO and water 
The method for the synthesis of colloidal cationic phosphonium gold nanoparticles in DMSO 
is reported for the first time in this work. These nanoparticles were obtained by a reduction of 
the gold salt in the presence of protecting ligands in DMSO. Colloidal cationic phosphonium 
gold nanoparticle solutions in water were also prepared for comparison purposes, following 
the principles involved in the method developed by Brust and Schifrin, a two-phase liquid-
liquid system.
35
 Variations were made to this protocol due to the solubility of the 
phosphonium ligands synthesised.  
Cationic phosphonium gold nanoparticles dispersed in DMSO 
In order to prepare the colloidal gold nanoparticles in DMSO, solutions of the phosphonium 
ligands, triphenylphosphoniopropylthiosulfate zwitterion, (3-
thioacetylpropyl)triphenylphosphonium bromide and tri(p-tolyl)phosphoniopropylthiosulfate 
zwitterion were prepared in DMSO (0.25 mmol, 0.30 mmol, and 0.8 mmol respectively). The 
volume used for these solutions was 20 mL. A solution of potassium tetrachloroaurate (0.12 
mmol) in DMSO (10mL) was also prepared. Then both, ligand and gold salt solutions were 
mixed and stirred. The reduction was carried out by adding 5 mL of freshly prepared aqueous 
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solution of sodium borohydride (2.0 mmol) to the DMSO mixture. In order to remove the 
excess of ligands in each one of the gold colloidal solutions prepared, liquid-liquid 
extractions were carried out using diethyl ether. 
Cationic phosphonium gold nanoparticles dispersed in water 
Solutions of the phosphonium ligands (triphenylphosphoniopropylthiosulfate zwitterion and 
(3-thioacetylpropyl)triphenylphosphonium bromide) was prepared in 20 mL of 
dichloromethane (DCM) (0.25 mmol, 0.30 mmol, 0.8 mmol respectively) and potassium 
tetrachloroaurate (0.12 mmol) was also added to the DCM solution.
35,36
 This was vigorously 
stirred for 2 hours and until the potassium gold salt was totally dissolved. The reduction of 
the gold (III) to gold (0) in the presence of phosphonium ligand was carried out by adding 
drop by drop a freshly prepared sodium borohydride solution in water (3ml, 400 mM) with 
vigorous stirring. After 20 minutes of stirring, 15 mL of deionised water was then added to 
the mixture. The latter is kept stirring overnight. The initial DCM was removed from the 
aqueous phase, as the functionalised nanoparticles transferred to this phase. Then, three 
liquid-liquid extractions were carried out using DCM in order to purify the cationic 
phosphonium gold nanoparticles dispersed in water. 
3. Results and Discussion 
(a) Synthesis of tri(p-tolyl)phosphoniopropylthiosulfate zwitterion 
The synthesis of the tri(p-tolyl)phosphoniopropylthiosulfate zwitterion involved the 
preparation of two intermediates, which were obtained and purified in order to get the 
zwitterion. The first compound synthesised was the hydroxylpropylphosphonium salt and this 
was obtained by the quaternisation of the tri(p-tolyl)phosphine with bromopropanol as it is 
showed in Scheme 1. The hydroxypropyl-tri(p-tolyl)phosphonium bromide was then treated 
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with HBr in order to obtain the -bromopropyl-tri(p-tolyl)phosphonium bromide. The latter 
is then reacted with Na2S2O3 in aqueous ethanol. The resulting zwitterion was purified by 
trituration using diethyl ether. The final product had an oil appearance, yellow coloured. 
When studied by ESMS in positive ion mode, ion corresponding to M+H
+
 was observed 
(459). The 
1
H NMR showed the distinctive chemical shift at 2.3 corresponding to the nine 
protons from the –CH3 attached to the aromatic ring. This chemical shift is the main 
difference between the tri(p-tolyl)phosphoniopropylthiosulfate and the 
triphenylphosphoniopropylthiosulfate 
1
H NMR spectra. It can be assumed that the sulfur-
sulfur bond of both tri(p-tolyl)phosphoniopropylthiosulfate undergoes cleavage with the loss 
of the sulfite ion under reductive conditions as in the synthesis of gold colloidal 
nanoparticles, as it was shown and reported in the case of the 
triphenylphosphoniopropylthiosulfate. This cleavage will allow the sulfur of the cationic 
phosphonium ligand to interact with the gold nanoparticle surface. As previously mentioned, 
these thiosulfate and thioacetate ligands are usually known as masked thiol ligands. For 
triphenylphosphoniopropylthiosulfate zwitterion and (3-
thioacetylpropyl)triphenylphosphonium bromide, similar results to the previously reported 
were observed when studied by IR, NMR and ESI-MS. Solubility tests were carried out to all 
three masked thiol ligands. They were soluble in methanol, ethanol, DMSO, chloroform and 
DCM. 
(b) Cationic phosphonium gold nanoparticles dispersed in DMSO and water 
The triphenylphosphoniopropyl thiosulfate and (3-thioacetylpropyl)triphenylphosphonium 
bromide ligands have shown their ability to functionalised and stabilised gold nanoparticles 
surface in water. For this work, another biocompatible solvent, DMSO, was used in order to 
assist with the solubilisation of more hydrophobic ligand (in our case the tri(p-
13 
 
tolyl)phosphoniopropyl thiosulfate zwitterion), its interaction with gold nanoparticle surface, 
and then penetration into the lipophilic cell wall. These thiosulfate containing salts are also 
known as Bunte salts. Shon et al. were the first in showing the production of alkanethiolate-
gold nanoparticles from Bunte salts.
37
 They used sodium S-dodecylthiosulfate and showed 
that the sulfur-sulfur bond of the thiosulfate salt undergoes cleavage and acted as the free 
thiol.
35,37
 Functionalised gold nanoparticles dispersed in water were obtained when 
triphenylphosphoniopropylthiosulfate and (3-thioacetylpropyl)triphenylphosphonium 
bromide ligands, and the two-phase liquid-liquid (DCM/water) method were used. However, 
when tri(p-tolyl)phosphoniopropylthiosulfate zwitterion was used as the protecting ligand 
with the same method, no transfer of these nanoparticles to the water phase was observed, 
and, therefore, no stable gold colloidal nanoparticles were obtained in water.  Various 
attempts of synthesising phosphonium cationic gold nanoparticles were carried out using 
tri(p-tolyl)phosphoniopropylthiosulfate zwitterion as the stabilising ligand and the two phase 
DCM/water method. Concentration of this ligand was also increased to a double (80 mM) 
and same results were obtained. Therefore, in the case of the tri(p-tolyl)phosphoniopropyl 
thiosulfate zwitterion, even increments in the concentration of the ligand did not help to the 
formation functionalised gold nanoparticles dispersed in water using the p-tolyl ligand.  
DMSO was chosen as an alternative solvent to disperse the gold nanoparticles functionalised 
with tri(p-tolyl)phosphoniopropylthiolate ligand. Due to the properties described in the 
introduction, DMSO was used to synthesise gold nanoparticle functionalised with the tri(p-
tolyl)phosphoniopropylthiosulfate zwitterion, and also be able to use more hydrophobic 
phosphonium ligands to fabricate carriers with potential abilities to permeate and penetrate 
the lipophilic cell walls.  
In order to prepare the colloidal gold nanoparticles in DMSO, a reduction of gold (III) to gold 
(0) was carried out in the presence of tri(p-tolyl)phosphoniopropylthiosulfate zwitterion in 
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DMSO, using sodium borohydride as the reducing agent. With this reducing method using 
DMSO as the dispersing solvent, a ruby – coloured colloidal solution of gold nanoparticle 
functionalised with tri(p-tolyl)phosphoniopropylthiolate was obtained. Using the same 
method in DMSO, other colloidal solutions of gold nanoparticles functionalised using 
triphenylphosphoniopropylthiosulfate zwitterion and (3-
thioactylpropyl)triphenylphosphonium bromide as protecting ligands were also successfully 
obtained. Stability studies were also carried out in order to monitor over time the potential 
aggregation in the colloidal solutions prepared following this method.  
(c) UV-Visible and TEM studies 
Using UV-Vis spectroscopy technique, formation of colloidal gold nanoparticles in DMSO 
(Figure 1) and as previously mentioned, stability of these solutions were monitored (Figures 2 
to 4).  
 
Figure 1. UV-visible absorption spectra of the colloidal solutions of gold nanoparticles 
functionalised with triphylphosphoniopropylthiosulfate zwitterion (TPPTS-AuNPs), (3-
thioacetylpropyl)triphenylphosphonium bromide (TPPTA-AuNPs), and tri(p-
tolyl)phosphoniopropylthiosulfate zwitterion (TTPTS-AuNPs) in DMSO, time = 0.  
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It is well-known that the dark-red colour of gold colloids dispersed in water reflects the 
surface plasmon band (SPB), which is a broad absorption band in the visible region around 
520 nm.
38
 The SPB is due to the collective oscillations of the electrons at the surface of 
nanoparticles (6s electrons of the conduction band for AuNPs) that is correlated with the 
electromagnetic field of the incoming light.
39
 The maximum and bandwidth are also 
influenced by the particle size.
40-43
 It has been shown that for gold nanoparticles of mean 
diameter of 9, 15, 22, 48, and 99 nm, the SPB maximum λmax was observed at 517, 520, 521, 
533, and 575 nm, respectively, in aqueous media.
40,44 
 
 
 
Figure 2. UV-visible absorption spectra of the colloidal solutions of gold nanoparticles 
functionalised using triphylphosphoniopropylthiosulfate zwitterion as protecting ligand 
(TPPTS-AuNPs). The different UV-visible spectra represent these nanoparticles dispersed in 
DMSO at time = 0, 6 and 12 weeks. 
 
16 
 
The method for the synthesis of colloidal gold nanoparticles in DMSO using triphenyl- and 
tri(p-tolyl)phosphoniopropylthiolate as protecting ligands is reported for the first time in this 
work. Evidence of the formation of gold nanoparticles using the reduction method in DMSO 
was shown by UV-Visible spectroscopy technique. Using the DMSO as the blank, bands 
centred at 519, 519 and 529 nm were observed in the resulting UV spectra (Figure 1) 
corresponding to the burgundy gold colloidal solutions prepared with 
triphenylphosphoniopropylthiosulfate (TPPTS-AuNPs), (3-
thioacetylpropyl)triphenylphosphonium bromide (TPPTA-AuNPs) and tri(p-
tolyl)phosphoniopropylthiosulfate (TTPTS-AuNPs), respectively. Their stability was also 
monitored by UV-Vis spectroscopy and the DMSO solutions showed to be stable at least for 
12 weeks (Figures 2, 3 and 4). The colloidal solutions were stored in the dark and at room 
temperature.  
As previously reported and repeated for this work for comparison purposes,
 35,36,45
 gold 
nanoparticles synthesised using triphenylphosphoniopropylthiosulfate and (3-
thioacetylpropyl)triphenylphosphonium bromide as protecting ligands, dispersed in water 
showed broad bands centred at 519 nm in both cases in the UV-visible spectra. When 
compared the UV spectra of the colloidal solutions of gold nanoparticles functionalised with 
triphenylphosphoniopropylthiolate in water and DMSO (time = 0), they did not show 
significant differences in the wavelengths. In our case the refractive index of the solvent 
DMSO has not shown to induce a shift of the SPB of our nanoparticles as suggested in the 
literature.
44 
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Figure 3. UV-visible absorption spectra of the colloidal solutions of gold nanoparticles 
functionalised using (3-thioacetylpropyl)triphenylphosphonium bromide as protecting ligand 
(TPPTA-AuNPs). The different UV-visible spectra represent these nanoparticles dispersed in 
DMSO at time = 0, 6 and 12 weeks. 
 
It is known that the ligand shell also alters the refractive index and causes either a red or blue 
shift.
41
 This shift is especially significant with thiolate ligands, which are responsible for a 
strong ligand field interacting with surface electron cloud.
41
 Similar evidence can be observed 
when compared the colloidal solutions in DMSO of gold nanoparticles stabilised with 
triphenylphosphoniopropylthiolate ligand with the one corresponding to gold nanoparticles 
functionalised with tri(p-tolyl)phosphoniopropylthiolate. Differences in wavelengths (519 
and 529 nm, respectively) can be observed when ligands change in structure (see Figures 2 
and 4).  
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Figure 4. UV-visible absorption spectra of the colloidal solutions of gold nanoparticles 
functionalised using tri(p-tolyl)phosphoniopropylthiosulfate zwitterion as protecting ligand 
(TTPTS-AuNPs). The different UV-visible spectra represent these nanoparticles dispersed in 
DMSO at time = 0, 6 and 12 weeks. 
 
The colloidal solutions of gold nanoparticles functionalised using triphenylphosphoniopropyl 
thiosulfate (Figure 5, TEM1), (3-thioacetylpropyl)triphenylphosphonium bromide (Figure 5, 
TEM2) and tri(p-tolyl)phosphoniopropylthiosulfate (Figure 5, TEM3) as protecting ligands, 
were all analysed by TEM. Micrographs of all three gold nanoparticle samples showed 
spherical or semi-spherical shaped particles. Then, particle sizes for samples TEM1, TEM2 
and TEM3 were obtained by analysing at least 150 particles per sample from several images 
taken.  
19 
 
  (TEM1) 
 (TEM2) 
(TEM3) 
Figure 5. Representative TEM micrographs of cationic phosphonium gold nanoparticles 
synthesised using triphenylphosphoniopropylthiosulfate (TEM1), (3-
thioacetylpropyl)triphenylphosphonium bromide (TEM2), and tri(p-
tolyl)phosphoniopropylthiosulfate (TEM3) as protecting ligands in DMSO, and 
corresponding particle size histograms. 
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All samples showed similar in particle sizes, and the mean values were obtained by 
calculating the averages and standard deviations. The calculated mean diameters were the 
followings: 11 ± 1 nm (TEM1), 8 ± 1 nm (TEM2) and 10 ± 1 nm (TEM3). Samples TEM1 
and TEM2 showed similar particle sizes to ones reported and synthesised using the two-phase 
DCM/water method.
35,36
 These evidences are confirmed by the ones found in the 
corresponding UV-Visible spectra. Although, solvents used to disperse the nanoparticles 
were different, the principle of the reduction method used and also the concentrations used 
for both methods, two phase DCM/water and DMSO, were similar.  
Gold nanoparticles in DMSO derived from triphenylphosphoniopropylthiosulfate zwitterion, 
and (3-thioacetylpropyl)triphenylphosphonium bromide are slightly different in size and in 
particle size distribution. This can be due to the differing passivation kinetics of the types of 
ligands used for this study, and the cleavage of the sulfur-sulfur and sulfur-carbon bonds in 
the thiosulfate and thioacetate species.
45
 The mechanisms of these cleavages are still unclear. 
However, the presence of water traces in the solvent used for the synthesis of colloidal gold 
nanoparticles, has shown to be crucial for the hydrolysis of the thiosulfate and thioacetate 
ligands and formation of alkylthiolates.
46,47
 These thiolate anions will lead to the formation of 
phosphonium-functionalised gold nanoparticles. The presence of reducing agent in the 
solution also influences the cleavage of sulfur-sulfur and sulfur-carbon bonds.
45 
In the case of the tri(p-tolyl)phosphoniopropylthiolate functionalised gold nanoparticles, they 
could only be produced using the DMSO method. The corresponding UV-Visible spectrum 
showed that the SPB is centred at 529 nm (Figure 4). With this evidence only, it could have 
been assumed that nanoparticles were slightly larger in size than the ones functionalised with 
the triphenylphosphoniopropylthiolate ligands, which showed bands centred at 519 nm 
(Figures 2 and 3). The slight blue shift observed in the UV-Visible spectrum of the tri(p-
tolyl)phosphoniopropylthiolate functionalised gold nanoparticles might be due to the ligand 
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shell altering the refractive index and interacting more strongly with the electron cloud of the 
nanoparticle surface, and not to the particle size. This evidence supports Su et al. 
experimental observations and results.
41
 
The agglomeration of nanoparticles can be observed in TEM1 and TEM3 micrographs 
(Figure 5). This recurrent experimental observation can be due to the use of drop deposition 
method for sample preparation. This technique is widely used for TEM sample preparation, 
however, according to studies reported in the literature,
48
 the use of this method can lead to 
agglomeration of particles at the substrate edges as the solvent evaporates. This accumulation 
will also depend on the sample concentration. No particle agglomeration can be observed in 
the case of gold nanoparticles prepared using (3-thioacetylpropyl)triphenylphosphonium 
bromide (TEM2, Figure 5). We can speculate that in this case, the sample concentration was 
lower than in the case of the solutions of gold nanoparticles prepared with the other two 
ligands.  
4. Conclusions 
The fabrication of cationic phosphonium gold nanoparticles using 
triphenylphosphoniopropylthiosulfate zwitterion, (3-thioacetylpropyl)triphenylphosphonium 
bromide and tri(p-tolyl)phosphoniopropylthiosulfate zwitterion as protecting ligands and a 
reduction method in DMSO is reported here for the first time; and also the synthesis of a new 
masked thiol, tri(p-tolyl)phosphoniopropylthiosulfate zwitterion. These Bunte salts and 
thioacetate ligands offer an advantage over the free thiol ligands as they showed better 
stability to air oxidation. The use of a biocompatible solvent such as DMSO to produce these 
nanoparticles can represent an advantage for their potential applications as novel therapeutic 
agents, especially, when more hydrophobic ligands (in our case, tri(p-
tolyl)phosphoniopropylthiosulfate zwitterion) are used to functionalised gold nanoparticles, 
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as they may have more affinity with the lipophilic cell walls. We have shown that under 
reductive conditions in DMSO, the formation of these nanoparticles occurred in the presence 
of all three cationic phosphonium ligands synthesised for this work. We have shown that the 
thiosulfate and thioacetate compounds convert into the corresponding thiolate anions. We can 
assume that these anions interact with the surface of the gold nanoparticles produced in situ 
when strong reducing agent is added to the DMSO solutions. The formation and the stability 
over time of triphenylphosphoniopropylthiolate and tri(p-tolyl)phosphoniopropylthiolate 
functionalised gold nanoparticles in DMSO were confirmed and followed by UV-visible 
spectroscopy.  Bands centred at 519 and 529 nm, respectively, were observed in the UV-
visible spectra, and those did not change over a period of 3 months. We can also speculate 
that the changes in the ligands chemical structure can affect the refractive index of the 
colloidal solution and produce a shift to the left (blue shift). As previously mentioned, tri(p-
tolyl)phosphoniopropylthiolate functionalised gold nanoparticles were successfully produced 
and dispersed in DMSO, however, these nanoparticles could not be obtained using the two-
phase liquid/liquid (DCM/water) method and dispersed in water. The TEM analyses of 
cationic phosphonium gold nanoparticles functionalised using 
triphenylphosphoniopropylthiosulfate and tri(p-tolyl)phosphoniopropylthiosulfate zwitterions 
as protecting ligands, showed similar particle sizes (11 nm). However, when (3-
thioacetylpropyl)triphenylphosphonium bromide used, the size of nanoparticles obtained was 
different (8 nm). This might be due to different passivation kinetics of the thiosulfate and 
thioacetate containing ligands. 
Visualisation of the cellular internalisation of our lipophilic cationic moieties containing gold 
nanoparticles by using flow cytometry technique is planned for future. This is a biophysical 
technique usually employed in the diagnosis of various health disorders. The cells are 
normally suspended in a stream of fluid and passed them by and electronic detection 
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apparatus. In order to prepare the samples for cytometry analysis, our cationic phosphonium 
gold nanoparticles are planned to be internalised by incubation.  
5. Characterisation of the cationic phosphonium ligands 
Hydroxypropyl-tri(p-tolyl)phosphonium bromide 
IR spectrum showed absorption bands at the regions of 725–720 cm-1 (  CH2), 1600cm
-1
 ( 
C-O), 3100–3000 cm-1(  CH-Aromatic), and 3344 cm-1 ( C-OH) . 1H NMR spectrum gave 
signals at  1.8 (9H,s 2CH3) ,  2.0 (2H,m, -CH2-),  2.6 (1H,s, OH),  3.4 (2H,m, P-CH2),  
3.6 (2H,t, OH-CH2) , and  7.3-7.5 (12H,m, Aromatic H) ppm. ESI-MS 363 [M - Br], 364 [M 
– Br] +[H+]. 
-bromopropyl-tri(p-tolyl)phosphonium bromide 
IR spectrum showed absorption bands at the regions of 677cm
-1
 ( C-Br), 748 cm-1 ( CH2), 
988 cm
-1
 ( P-CH2), and 3100–3000 cm
-1
( CH-Aromatic). 1H NMR spectrum gave signals 
at  2.3 (9H,s, -CH3) ,  2.4(2H,m, P-CH2) ,   3.8  (2H,m, -CH2-) and  at  7.4- 7.9 (12H,m, 
Aromatic H) ppm.  ESI-MS 427 [M]. 
Tri(p-tolyl)phosphoniopropylthiosulfate zwitterion 
IR spectrum showed absorption bands at the regions of 725–720 cm-1, ( CH2), 1329cm
-1
 ( 
S=O), 1400 cm
-1
 ( C-S), 3100–3000 cm-1 ( CH-Aromatic). 1H NMR showed a signals at   
2.3 (s,9H, 3CH3) ,  3.2 (t, 2H , P-CH2-CH2-CH2) ,  3.4 (t, 2H , P -CH2-CH2-CH2) ,  3.6 
(m, 2H , P-CH2-CH2-CH2),  7.24 (1H , CDCL3), and   7.3-7.6 (12H,m, Aromatic H) ppm. 
ESI-MS 459 [M + H
+
]. 
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Triphenylphosphoniopropylthiosulfate zwitterion 
IR spectrum showed absorption bands at the regions IR spectrum showed absorption bands at 
the regions of 725–720 cm-1 (  CH2), 1330 cm
1
 (  S=O), 1345 cm-1 (C-S-), and 3100–3000 
cm
-1 
( CH-Aromatic). 1H NMR spectrum gave signals at  2.2 (2H,m, P-CH2-CH2-CH2) ,  
3.3 (2H,m, P-CH2-CH2-CH2) ,   4.0  (2H,m, P-CH2-CH2-CH2) and  at  7.6 - 7.8 (15H,m, 
Aromatic H) ppm. ESI-MS 417 [M + H
+
]. 
(3-Thioacetylpropyl)triphenylphosphonium bromide 
IR spectrum showed absorption bands at the regions of 735–740 cm-1 ( CH2), 1345 cm
-1
 ( 
C-S), 1470–1450 cm-1 ( C–H corresponding to bend-CH2), 1678 cm
-1
 ( C=O), and 3100–
3000 cm
-1
( CH-Aromatic).  1H NMR showed a signals at    2.4 (3H,s, -CH3),  2.9 (2H,m, 
P-CH2-CH2-CH2),  3.8 (2H,m, P-CH2-CH2-CH2),  4.1 (2H,m, P-CH2-CH2-CH2), and  7.6-
7.9 (15H,m, Aromatic H) ppm. ESI-MS 380 [M + H
+
]. 
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